COX-2 (SP21)

Skip to Content

Skip over Generic Navigation

  • Select your country:
DIAGNOSTICS F. Hoffmann-La Roche Ltd

COX-2 (SP21)

COX-2 (SP21), colon carcinoma, 130x
Catalog Number:760-4254
Ordering Code:05269148001
Quantity:50 tests
Controls:Colon Adenocarcinoma
Clone Name:SP21
Regulatory Status:IVD

Cyclooxygenase-2 catalyzes the conversion of arachidonic acid to prostaglandin H2 in the first step in the biosynthesis of prostaglandins, thromboxanes, and prostacyclins. COX-2 inhibition by nonsteroidal antiinflamatory agents has been shown to decrease angiogenesis, and tumor growth, and promote apoptosis. COX-2 overexpression has been associated with increased microvascular density, and VEGF protein expression in head and neck squamous cell carcinoma and is a poor prognostic indicator in this entity as well. COX-2 overexpression has also been suggested as a poor prognostic indicator in carcinomas of the colon, breast, pancreas, and adenocarcinoma of the lung.

Health Care Provider Notice
This website is intended for healthcare professionals only.

The content on this website is intended for healthcare professionals only. Information intended for the general public can be found on Please confirm that you are a medical professional before accessing the content of this website.

Yes, I hereby certify that I am a healthcare professional. Continue
Third-Party Link Disclosure
Disclosure for Links to Third-Party Websites

You are now leaving the Roche website. The site you are about to visit is operated by third-parties. The link to this site neither makes nor implies any representation or warranty for any products or services offered on a third-party site and is intended only to enable convenient access to the third-party site and for no other purpose.